Mechanism & research context
Semaglutide is a 31-amino-acid GLP-1 analogue modified with a C18 fatty-acid chain for extended albumin binding. It is widely used in laboratory studies of GLP-1 receptor signalling, β-cell response and in-vitro models of energy balance. Supplied as lyophilized powder at ≥98% HPLC purity.
Selected studies
"Once-weekly semaglutide 2.4 mg produced a mean ~15% reduction in body weight, making it the first GLP-1 receptor agonist approved for chronic weight management."
New England Journal of Medicine — STEP-1 trialView study
Use disclaimerFor Research Use Only. Not for Human Consumption. Not a drug, food, or cosmetic.
Article reflects published preclinical and in-vitro literature..